Ulcerative Colitis Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Ulcerative Colitis remains an active clinical development field. Clinical competition is shifting from broad immunosuppression toward pathway-selective control, durable remission and treatment strategies that reduce steroid exposure without trading away safety. The PatSnap evidence set used here contains 1,245 matched trial records and 1,470 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07700446 | Upadacitinib hemihydrate | Phase 4; Not yet recruiting | Sponsor not listed | Geography not listed | To determine the rate of re-capture of clinical response per adapted Mayo score at week 8 or week 16 (pooled). (Baseline, week8 and 16) | 2029-11-01 |
| NCT07697456 | FG-M701 + Risankizumab-RZAA | Phase 2; Not yet recruiting | AbbVie, Inc. | Belgium, United States, Japan, South Africa, Slovenia +4 more | Crohn's Disease Specific: Percentage of Participants Achieving Endoscopic Remission (At Week 28); Ulcerative Colitis Specific: Percentage of Participants who Achieve Endoscopic Remission (At Week 28) | 2031-10-01 |
| CTR20262583 | AC-101 | Phase 2; 进行中 （尚未招募） | Accro Bioscience (Suzhou) Co., Ltd. | China | (第12周) | Timing not listed |
| NCT07694609 | Intervention not normalized | Not Applicable; Active, not recruiting | Sponsor not listed | Italy | Change in Work Ability Index (WAI) Score From Baseline to 12 Months (Baseline and 12 months) | 2027-10-23 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Randomized, Double-blind, Phase 2 Study to Evaluate the Efficacy and the Safety of OSE-127 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Previous Treatment(s) (Phase 2): the indexed record reports Change From Baseline in Modified Mayo Score (MMS) at Week 10(Least Squares Mean) = -1.52 units on a scale (95% Confidence Interval, -2.14 to -0.90); Change From Baseline in Modified Mayo Score (MMS) at Week 10(Least Squares Mean): Least Square Mean Difference = -0.90(95% CI, -1.73 to -0.06), P-Value = 0.036; Least Square Mean Difference = -1.16(95% CI, -2.12 to -0.19), P-Value = 0.019; Change From Baseline in Modified Mayo Score (MMS) at Week 10(Least Squares Mean): Least Square Mean Difference = -0.90(95% CI, -1.73 to -0.06), P-Value = 0.036; Least Square Mean Difference = -1.16(95% CI, -2.12 to -0.19), P-Value = 0.019.
- A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE) (Phase 2): the indexed record reports AE = 15 Participants; AE = 11 Participants; -.
- A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis (Phase 2): the indexed record reports Change From Baseline in Modified Mayo Score (MMS) at Week 12(Least Squares Mean): LS Mean Difference = -0.18(90% CI, -1.33 to 0.97); LS Mean Difference = 0.12(90% CI, -1.03 to 1.28); Change From Baseline in Modified Mayo Score (MMS) at Week 12(Least Squares Mean) = -2.11 score on a scale (Standard Error, 0.59); Change From Baseline in Modified Mayo Score (MMS) at Week 12(Least Squares Mean) = -1.98 score on a scale (Standard Error, 0.40).
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Upadacitinib hemihydrate (Approved; JAK1), FG-M701 (Phase 1; TL1A), Risankizumab-RZAA (Approved; IL-23p19), AC-101 (Phase 2; RIPK2). Company & Deal Intelligence records identify sponsor context for AbbVie, Inc. (ABBV), Accro Bioscience (Suzhou) Co., Ltd.. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Standard definitions for steroid-free remission and durable disease control.
- Head-to-head trials against current targeted standards, not placebo alone.
- Biomarker strategies that distinguish mechanistic responders before prolonged treatment.
- Long-term infection, malignancy and immune-reconstitution follow-up.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Ulcerative Colitis has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
